AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for inducing antigen-specific T-cell tolerance or non-responsiveness of donor T-cells to desired alloantigen-bearing cells *ex vivo* comprising the following:

(i) purifying $CD4^+$ T-cells from donor tissue;

(ii) irradiating alloantigen-bearing cells obtained from a recipient to deplete recipient T-cells;

(iii) producing a mixed lymphocyte reaction culture comprising the purified donor $CD4^+$ T-cells and irradiated, T-cell depleted alloantigen-bearing cells obtained from a recipient;

(iv) adding an anti-gp39 antibody to the culture, thereby initiating a mixed lymphocyte reaction culture comprising purified donor $CD4^+$ T-cells, T-cell depleted recipient alloantigen-bearing cells, and anti-gp39 antibody;

(v) maintaining the mixed lymphocyte reaction culture *ex vivo* for a sufficient time to render the donor $CD4^+$ T-cells substantially tolerant or non-responsive to said alloantigen-bearing cells, and

(vi) assaying *ex vivo* for induction of donor $CD4^+$ T-cell tolerance or non-responsiveness.

2. (Previously Presented) The method of Claim 1, wherein the donor tissue is donor bone marrow or peripheral blood cells.

3. (Canceled)

4. (Previously Presented) The method of Claim 1, wherein the gp39 antibody is an anti-human gp39 monoclonal antibody.

5. (Previously Presented) The method of Claim 4, wherein said anti-gp39 antibody is a chimeric or humanized anti-human gp39 monoclonal antibody.

6. (Currently Amended) The method of Claim 1, wherein the donor T-cells are cultured in step (v) for a time ranging from about ~~5~~ 1 to 30 days.

7. (Currently Amended) The method of Claim 6, wherein said donor T-cells are cultured in step (v) for a time ~~ranging from 6 to~~ of about 10 days.

8-9. (Canceled)

10. (Previously Presented) The method of Claim 1, wherein the donor T-cells that have been determined to be tolerized by the assay of step (vi) are transplanted into a recipient in need of such transplantation.

11. (Original) The method of Claim 10, wherein the recipient is in need of immune reconstitution as a result of disease or disease treatment.

12. (Canceled)

13. (Previously Presented) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises measuring IL-2 concentration in the cell culture medium supernatants of the donor T-cells cultured in step (v) and of control donor T-cells, wherein detection of reduced IL-2 concentration in the supernatant of the donor T-cells cultured in step (v), relative to the IL-2 concentration in the supernatant of control T-cells, is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.

14. (Withdrawn; Currently Amended) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness in step (vi) comprises measuring the concentration of interferon-gamma in the cell culture medium supernatants of the donor T-cells as cultured in step ~~iv~~ (iv) and of control donor T-cells,

wherein detection of reduced interferon-gamma concentration in the supernatant of the donor T-cells as cultured in step ~~iv~~ (iv) relative to that of the control T-cells is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.

15. (Withdrawn; Currently Amended) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness in step (vi) comprises assaying to detect at least one antigen selected from the group consisting of L-selectin, ICAM-1, and CD45 in the donor T-cells as cultured in step ~~iv~~ (iv) and control donor T-cells,

wherein detection of an increased amount of L-selectin or ICAM-1, or a reduced amount of CD45 in the donor T-cells as cultured in step ~~iv~~ (iv) relative to that in the control donor T-cells is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.